NewTimeSpace (newtimespace.com) News, By the close of trading on Jul 17, 2026, Z.AI(02513.HK) saw a loss of 28.49% in its share price, closing at HKD 1107. During the session, it reached an intraday high of HKD 1434 and touched an intraday low of HKD 1085.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jul 17, 2026, XIZHI TECH-P(01879.HK) saw a loss of 19.34% in its share price, closing at HKD 270.2. During the session, it reached an intraday high of HKD 335 and touched an intraday low of HKD 267.6.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jul 17, 2026, HJ SCIENCE-B(06132.HK) saw a loss of 9.79% in its share price, closing at HKD 38.34. During the session, it reached an intraday high of HKD 42.48 and touched an intraday low of HKD 37.52.
NewTimeSpace News: The Stock Exchange of Hong Kong Limited (HKEX) has taken disciplinary action against three former directors of JIAYUAN SER (01153.HK). A statement of unfitness to act as a director was issued against former Chairman Zhu Hongge, while former executive directors Bao Guojun and Pang Bo received statements of prejudice to investors’ interests together with formal reprimands. Between January 2021 and December 2022, JIAYUAN SER completed 398 unauthorised fund transfers aggregating around RMB1.995 billion to entities controlled by controlling shareholder Shen Tianqing, including IPO proceeds, with an unrecovered net amount of approximately RMB644 million.
NewTimeSpace News: CSPC Pharma (01093.HK) announced that the New Drug Application (NDA) for its self-developed Envi Trastuzumab Injection has been accepted by the NMPA. Filed as Class 1 therapeutic biological product, it is indicated for unresectable or metastatic HER2-positive adult breast cancer patients previously treated with one or more anti-HER2 agents.
NewTimeSpace News: B&K CORP-B (02396.HK) announced that its full Chinese corporate name has been revised from Huaren Biotech (Qingdao) Co., Limited to Qingcheng New Drug Biotech (Qingdao) Co., Limited, effective 13 July 2026. The Chinese stock short name will switch from Huaren Biotech-B to Qingcheng New Drug-B for trading commencing at 9:00 a.m. on 22 July 2026, while stock code 02396 remains unchanged.
NewTimeSpace News: TE Healthcare (06877.HK) issued a profit positive forecast and litigation update announcement. Based on preliminary assessment, the Group expects to record consolidated profit attributable to owners of the Company of approximately HK$1 million for the six months ended 30 June 2026, versus a loss of around HK$2.2 million in the corresponding period last year, representing a turnaround to profitability. The positive swing is mainly driven by revenue growth from expanded healthcare services and retail B2C business.
NewTimeSpace News: On 17 July 2026, XPENG-W(09868.HK) fluctuated lower in the afternoon session. As of 15:13, its intraday price stood at HK$51.70, representing a drop of 8.58%. On 16 July, XPEV Group held the XPEV Brand Day and global launch event of MONA L03 in Munich, Germany, unveiling the first global model of the MONA series, the XPEV MONA L03.
NewTimeSpace (newtimespace.com) reported that on July 17, 2026, the semiconductor theme in Hong Kong stocks continued to weaken, with ASMPT (00522.HK) extending its decline. As of 13:38, the stock was quoted at HKD 159.900, down 9.92%.
NewTimeSpace (newtimespace.com) reported that on July 17, 2026, the humanoid robot theme weakened significantly, with Xiaomi-W (01810.HK) fluctuating lower. As of 13:13, the stock was quoted at HKD 26.660, down 3.05%.
The HKIC 2025 Annual Report highlights total assets of HKD 69.7 billion, an operating profit of HKD 6.32 billion (+181% YoY), and a portfolio net IRR of 14%. The corporation's strategic framework has transitioned from pure capital allocation to deep industrial empowerment in hard technology, from isolated project investments to comprehensive ecosystem building, and from local operations to global connectivity via "Belt and Road" technology exports. In 2026, HKIC will expand its investment focus into frontier sectors such as next-generation AI, brain-computer interfaces, and commercial aerospace, prioritizing Greater Bay Area integration, cross-border infrastructure, and global market expansion.
NewTimeSpace News: July 16, 2026, PUBLIC FIN HOLD(00626.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 692.22 million, increased by 1.03% YoY
NewTimeSpace (newtimespace.com) News, PINE TECH (01079.HK) plans to conduct a rights issue on the basis of \\"2 for 1\\", with estimated net proceeds of HKD 105 million.
NewTimeSpace (newtimespace.com) News, WAN LEADER (08482.HK) plans to issue in total 44.92 million shares by subscription, with estimated net proceeds of HKD 4.55 million.
NewTimeSpace News: On July 17, Unisound announced the official release of the industry's first professional large model "U2-Med Three Medical Model" targeting medical care, medical insurance (including commercial insurance) and pharmaceuticals, based on the U2 foundation model. The model significantly improves computational efficiency and intelligent agent execution to support three-medical linkage digital transformation, and ranked first in both the full-modality large model and intelligent agent categories in the July 2026 MedBench evaluation, with three-medical comprehensive benchmark scores of 89.1 (non-thinking mode) and 88.9 (thinking mode). The Company also recently signed AI medical construction projects with leading top-tier hospitals including Beijing You'an Hospital, Shandong Provincial Hospital and Nanjing Tongren Hospital, marking its entry into a new phase of scalable replication for medical large model commercialization.
NewTimeSpace News: On July 16, Wang On Group and Wai Yuen Tong jointly announced that an indirect wholly-owned subsidiary of Wai Yuen Tong, as seller, agreed to sell the entire equity interest in Guanzun (Shenzhen) Commercial & Trading Development Co., Ltd.—which holds a property in Shenzhen Pingshan comprising a site of approximately 11,026.83 sq.m. and one factory and two dormitory buildings—to the buyer for RMB 99.8 million (approx. HK$115.44 million). The independent valuation of the property is approximately RMB 99.3 million. The transaction constitutes a major transaction for both parties; Wang On will convene an EGM for approval, while Wai Yuen Tong has obtained written approval from a Wang On subsidiary holding 72.71% of its shares. Upon completion, both groups expect to record a gain of approximately HK$46.54 million, and Wai Yuen Tong intends to apply the proceeds to general working capital.
